Bryant Ranch Prepack Initiates Class III Recall of Cephalexin Oral Suspension Due to Critical Labeling Error
Bryant Ranch Prepack, Inc. has initiated a Class III nationwide recall (D-0538-2024) for 104 bottles of Cephalexin for Oral Suspension, USP, 250mg/5mL. This action stems from a critical labeling error where the back label incorrectly stated 5g of cephalexin monohydrate instead of the correct 10g per bottle. This event underscores the imperative for rigorous quality control in pharmaceutical relabeling operations.
FDA Initiates Class III Recall for Cephalexin Oral Suspension Due to Labeling Error
On May 10, 2024, Bryant Ranch Prepack, Inc., located in Burbank, CA, initiated a voluntary, firm-initiated Class III recall (D-0538-2024) for 104 bottles of Cephalexin for Oral Suspension, USP, 250mg/5mL. This critical action was prompted by a significant labeling error on the product's back label. Specifically, the label incorrectly stated 'Each contains: cephalexin monohydrate, USP equivalent to 5g' when the correct declaration should have been 'Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'. This discrepancy represents a 50% misrepresentation of the total active pharmaceutical ingredient (API) content per bottle. For procurement directors and supply chain VPs, this event underscores the immediate need to scrutinize quality control checkpoints, particularly in outsourced packaging and relabeling operations. A Class III recall, while indicating a low probability of adverse health consequences, still triggers significant operational costs related to product retrieval, inventory management, and regulatory reporting. The affected product, distributed nationwide in the USA, includes multiple lots (235287, 235629, 235805, 236292, 237022, 237308, 237748) with an expiration date of December 31, 2025. This incident highlights that even seemingly minor errors in labeling can lead to widespread market disruption and regulatory intervention, demanding immediate attention to quality assurance protocols.
Supply Chain Vulnerabilities in Pharmaceutical Relabeling Operations
The Cephalexin for Oral Suspension, USP, 250mg/5mL, subject to this recall, was originally manufactured by Alkem Laboratories Ltd. and subsequently relabeled by Bryant Ranch Prepack, Inc. This dual-entity involvement highlights a common vulnerability within the pharmaceutical supply chain where contract packaging and relabeling introduce additional layers of quality control responsibility. The incorrect NDC (National Drug Code) 63629-8858-1, associated with the mislabeled product, directly traces back to Bryant Ranch Prepack's relabeling process. For regulatory affairs heads and supply chain VPs, this incident necessitates a thorough review of existing quality agreements with third-party relabelers. It is imperative to ensure that these agreements explicitly define responsibilities for label verification, artwork approval, and final product release. The failure to detect a 50% discrepancy in stated API content at the relabeling stage indicates a potential lapse in critical inspection points. Companies relying on contract services must implement robust audit programs and require detailed documentation of every stage of the relabeling process, from artwork receipt to final packaging, to prevent similar, commercially damaging errors from reaching the market. This proactive approach is crucial to maintaining product integrity and avoiding costly recalls.
Regulatory Compliance and Market Repercussions for Bryant Ranch Prepack
The FDA's classification of this event as a Class III recall signifies that while the use of, or exposure to, the mislabeled Cephalexin for Oral Suspension is not likely to cause adverse health consequences, the product still violates FDA regulations. For Bryant Ranch Prepack, Inc., this voluntary recall, initiated on May 10, 2024, and classified by the FDA on June 4, 2024, carries significant commercial and reputational implications. Despite the lower risk profile of a Class III recall compared to Class I or II, the event still triggers a mandatory reporting and remediation process, consuming valuable company resources. Business development executives must recognize that such regulatory actions, even for labeling errors, can erode customer trust and impact future contract opportunities. Clients in the pharmaceutical sector demand impeccable quality and regulatory adherence, making a recall event a serious impediment to securing new business. Regulatory affairs teams at Bryant Ranch Prepack will be required to submit detailed reports to the FDA outlining the root cause of the labeling error, the corrective and preventive actions (CAPA) implemented, and the effectiveness checks to prevent recurrence. Failure to adequately address these issues could lead to heightened FDA scrutiny, including potential inspections or further regulatory actions, underscoring the critical importance of immediate and comprehensive remediation.